From Stroke Risk to Renal Risk: The Evolving Utility of CHAâ‚‚DSâ‚‚-VASc

Abstract

Primary percutaneous coronary intervention (PCI) remains the cornerstone of reperfusion in ST-segment elevation myocardial infarction (STEMI). However, alongside rapid restoration of coronary blood flow, clinicians must remain vigilant for contrast-associated acute kidney injury, a complication consistently linked with prolonged hospitalization, increased morbidity, and adverse cardiovascular outcomes [1-4]. In this context, the availability of a simple and immediately applicable risk stratification tool becomes highly relevant, particularly in time-sensitive clinical environments where procedural decisions are made rapidly [3,5,6]. In this issue of the Pakistan Heart Journal, Ajmal et al. [7] evaluate whether the CHA₂DS₂-VASc score—originally developed for thromboembolic risk estimation in atrial fibrillation—can be repurposed to predict contrast-induced nephropathy (CIN) in STEMI patients undergoing primary PCI. Their findings provide important clinical insight. In a prospective cohort of 218 patients, CIN occurred in 37.2%. At a cutoff of ≥4, the score demonstrated high specificity (97.81%) and strong positive predictive value (91.89%), although sensitivity remained modest (41.98%). The area under the curve (AUC) of 0.70 further indicates fair discriminatory ability, and each incremental increase in score independently increased the odds of CIN. Collectively, these findings suggest that the CHA₂DS₂-VASc score is better suited as a rule-in tool rather than a universal screening instrument. This distinction is clinically meaningful. In acute STEMI care, clinicians frequently operate in settings where comprehensive risk models are impractical at first contact. Established tools such as Mehran-derived scores provide valuable prognostic information but depend on procedural or peri-procedural variables that may not be immediately available [3,4,6]. In contrast, the CHAâ‚‚DSâ‚‚-VASc score can be calculated at the bedside using readily available clinical data. Its value, therefore, lies not in replacing established models but in offering an early, pragmatic estimate of risk when rapid decision-making is required. The biological plausibility of this approach is also compelling. The components of the CHA₂DS₂-VASc score—including age, hypertension, diabetes, heart failure, vascular disease, prior cerebrovascular events, and sex—reflect cumulative cardiovascular burden and parallel mechanisms contributing to renal vulnerability. This overlap explains why the score has increasingly been explored beyond atrial fibrillation, particularly in acute coronary syndromes and PCI populations [8-10]. However, variability in cutoff thresholds and performance metrics across studies underscores the importance of contextual interpretation. At the same time, caution is warranted. The relatively low sensitivity observed in this study highlights that a low CHA₂DS₂-VASc score should not be interpreted as reassurance. A substantial proportion of patients who develop CIN may fall below the high-risk threshold. Accordingly, the score should not replace clinical judgment or established preventive strategies, including optimized hydration, minimization of contrast exposure, avoidance of nephrotoxic agents, and vigilant post-procedural monitoring [3,4,6]. Instead, it should be viewed as an adjunct—useful for identifying a subgroup of patients in whom preventive vigilance should be intensified. An important strength of this study lies in its pragmatic relevance. Rather than focusing on highly selected populations, it addresses a question directly applicable to everyday cardiology practice: can a familiar and readily available clinical score provide early risk insight? In high-volume or resource-constrained settings, where time and infrastructure may limit the use of complex models, such tools have particular value. While emerging approaches, including biomarker-based and machine learning models, may offer improved predictive performance, their widespread implementation remains dependent on accessibility and integration into clinical workflows [4,11]. Nevertheless, the findings should be interpreted in light of several limitations. The single-center design, exclusion of patients with advanced chronic kidney disease, and incomplete incorporation of procedural variables such as contrast volume and hydration protocols may influence both generalizability and observed diagnostic performance. As such, this study does not establish the CHAâ‚‚DSâ‚‚-VASc score as a replacement for established renal risk models. Rather, it supports its role as an early, accessible risk indicator within a broader clinical framework. Looking forward, future research should focus on integrating simple clinical scores such as CHA₂DS₂-VASc with procedural variables, novel biomarkers, and emerging predictive models to enhance risk stratification accuracy. Comparative studies with established tools, including Mehran-based models, will be essential to define its incremental value and optimal clinical positioningThe editorial message is clear: in acute cardiovascular care, the utility of a risk tool depends not only on its statistical performance, but also on its timing, practicality, and clinical context. Ajmal et al. demonstrate that a familiar score can offer meaningful early insight. While the CHA₂DS₂-VASc score does not provide a complete solution, it may help clinicians identify high-risk patients early enough to influence care—where it matters most [8-10]. References Khalfallah M, Allaithy A, Maria D. Incidence, predictors and outcomes of contrast induced nephropathy in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Glob Heart.2021;16(1):57. DOI: 10.5334/gh.1071 Mohebi R, Karimi Galougahi K, Garcia JJ, Horst J, Ben-Yehuda O, Radhakrishnan J, et al. Long-term clinical impact of contrast-associated acute kidney injury following PCI: an ADAPT-DES substudy. JACC Cardiovasc Interv. 2022;15(7):753-66. DOI: 10.1016/j.jcin.2021.11.026 Isaac T, Gilani S, Kleiman NS. Contrast-associated acute kidney injury in percutaneous cardiovascular interventions: incidence, predictors, and prognostic value. Methodist Debakey Cardiovasc J. 2022;18(4):73-85. DOI: 10.14797/mdcvj.1136 Mandurino-Mirizzi A, Munafò A, Crimi G. Contrast-associated acute kidney injury. J Clin Med. 2022;11(8):2167. DOI: 10.3390/jcm11082167 Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18-e114. DOI: 10.1161/CIR.0000000000001038 Ajmal MA, Kauser S, Farooq U, Saleem S, Munim A, Aslam O. Diagnostic Performance of the CHAâ‚‚DSâ‚‚-VASc Score for Predicting Contrast-Induced Nephropathy in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study. Pak Heart J. 2026;59(02):280-287. DOI: 10.47144/phj.v59i2.3287 Ali ZA, Escaned J, Dudek D, Radhakrishnan J, Karimi Galougahi K. Strategies for renal protection in cardiovascular interventions. Korean Circ J. 2022;52(7):485-95. DOI: 10.4070/kcj.2022.0093 Fang C, Chen Z, Zhang J, Jin X, Yang M. Association of CHA2DS2-VASc score with in-hospital cardiovascular adverse events in patients with acute ST-segment elevation myocardial infarction. Int J Clin Pract.2022;2022:3659381. DOI: 10.1155/2022/3659381 Samir A, Gabra W, Alhossary H, Bakhoum S. Predictive value of CHA2DS2VASC score for contrast-induced nephropathy after primary percutaneous coronary intervention for patients presenting with acute ST-segment elevation myocardial infarction. Egypt Heart J. 2023;75(1):52. DOI: 10.1186/s43044-023-00378-x Dönmez E, Özcan S, İnce O, Şahin İ, Okuyan E. Predictive value of CHA2DS2-VASc score in patients with contrast-induced nephropathy after primary percutaneous coronary intervention for ST-elevated myocardial infarction. Turk Kardiyol Dern Ars. 2023;51:97-103. DOI: 10.5543/tkda.2022.46994 Zhang J, Chen H, Yu L, Han W. Machine learning prediction of contrast-induced AKI after PCI using the systemic immune-inflammation index: insights from MIMIC-IV. Ren Fail. 2026;47:2610913. DOI: 10.1080/0886022X.2025.2610913